Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database
Autore:
Fleischhacker, WW; Lemmens, P; van Baelen, B;
Indirizzi:
Innsbruck Univ Clin, Dept Biol Psychiat, A-6020 Innsbruck, Austria Innsbruck Univ Clin Innsbruck Austria A-6020 , A-6020 Innsbruck, Austria Janssen Res Fdn, B-2340 Beerse, Belgium Janssen Res Fdn Beerse Belgium B-2340 en Res Fdn, B-2340 Beerse, Belgium
Titolo Testata:
PHARMACOPSYCHIATRY
fascicolo: 3, volume: 34, anno: 2001,
pagine: 104 - 110
SICI:
0176-3679(200105)34:3<104:AQAOTN>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC-SCHIZOPHRENIC PATIENTS; DOUBLE-BLIND; EXTRAPYRAMIDAL SYMPTOMS; PARALLEL-GROUP; 1ST EPISODE; HALOPERIDOL; MULTICENTER; CLOZAPINE; EFFICACY; PLACEBO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Fleischhacker, WW Innsbruck Univ Clin, Dept Biol Psychiat, Anichstr 35, A-6020 Innsbruck, Austria Innsbruck Univ Clin Anichstr 35 Innsbruck Austria A-6020
Citazione:
W.W. Fleischhacker et al., "A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database", PHARMACOPS, 34(3), 2001, pp. 104-110

Abstract

Background: Neurological side effects of antipsychotic agents limit the use of these drugs, and development of newer antipsychotic agents has been focused on a reduced risk of extrapyramidal symptoms (EPS) as well as effective symptom control. Methods: A qualitative analysis of EPS was performed using Extrapyramidal Symptom Rating Scale (ESRS) data from 11 double-blind risperidone trials. An ESRS factor analysis and maximum changes in ESRS scores were compared for the risperidone, haloperidol, and placebo groups. Results: The factor analysis revealed five factors. Between-group comparisons showed no differences between placebo and 1 to 2 mg/day-risperidone groups. Parkinsonism, tremor, akathisia, and sialorrhea were more likely to occur with haloperidol than with placebo or risperidone at 1 to 6 mg/day. Similar results were noted by maximum changes in ESRS scores. At risperidone doses of more than 8 mg/day, acute EPS severity lay between that of the placebo and haloperidol groups. The severity of tardive dyskinesia was greater in patients receiving placebo than in those receiving either active treatment. Conclusions: As the results described above were derived from a post hoc analysis of an existing database, conclusions must remain tentative. To providemore definitive answers, EPS assessments in future studies should be refined to more accurately predict the type of EPS expected with a given agent in clinical practice.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/12/19 alle ore 11:08:05